


Incorporation of Nonproteinogenic Amino Acids in Class I and II Lantibiotics

Nidhi Kakkar,[†] Jessica G. Perez,[§] Wenshe R. Liu,[‡] Michael C. Jewett,[§] and Wilfred A. van der Donk^{*,†}[†]Howard Hughes Medical Institute and Roger Adams Laboratory, Department of Chemistry, University of Illinois at Urbana—Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States[‡]Department of Chemistry, Texas A&M University, College Station, Texas 77843m United States[§]Department of Chemical and Biological Engineering, Northwestern University, Evanston, Illinois 60208, United States

S Supporting Information

ABSTRACT: Lantibiotics are ribosomally synthesized and post-translationally modified peptide natural products that contain thioether cross-links formed by lanthionine and methyllanthionine residues. They exert potent antimicrobial activity against Gram-positive bacteria. We herein report production of analogues of two lantibiotics, lactacin 481 and nisin, that contain nonproteinogenic amino acids using two different strategies involving amber stop codon suppression technology. These methods complement recent alternative approaches to incorporate nonproteinogenic amino acids into lantibiotics.



The extensive genome sequencing efforts of the past decade have provided unparalleled information regarding the potential capacity of organisms to produce highly diverse biologically active natural products. One large class of such molecules is ribosomally synthesized and post-translationally modified peptides (RiPPs),¹ including the largest group of RiPPs, the lanthipeptides.^{2–5} These molecules are characterized by the presence of thioether cross-links in the bisamino acids lanthionine and methyllanthionine that have given lanthipeptides their name. They are biosynthesized from a linear precursor peptide called LanA, which comprises an N-terminal segment called the leader peptide that is important for recognition by the post-translational modification enzymes, and a C-terminal segment called the core peptide that after processing results in the mature natural product. For class I lanthipeptides, a LanB enzyme first dehydrates select Ser and Thr residues to dehydroalanine (Dha) and dehydrobutyrine (Dhb), respectively, and then a LanC cyclase promotes Michael-type additions of Cys residues to the dehydro amino acids to form the thioether rings (e.g., Figure 1). In class II lanthipeptides, a bifunctional enzyme LanM performs both dehydration and cyclization reactions (e.g., Figure 2). Many lanthipeptides possess antimicrobial activity and are called lantibiotics. These cyclic peptides have garnered increasing attention with respect to engineering for three main reasons. First, they are ribosomally synthesized, and hence variants of the precursor peptide can be made with relative ease using mutagenesis. Second, the biosynthetic enzymes have been shown to be inherently promiscuous, facilitating analogue formation. And third, the post-translational modifications, by restricting the conformational flexibility, allow for higher chemical stability and tighter and/or more specific binding to

the natural target, thereby improving the bioavailability and bioactivity.^{1,4,6,7}

Many efforts have been made to increase the diversity of lantibiotics by site-directed mutagenesis to afford variants with substitutions by proteinogenic amino acids.^{8–19} More recently, several studies have also shown the potential of expanding the repertoire of substitutions to nonproteinogenic amino acids (or unnatural amino acids, UAAs) for a subset of lanthipeptides.^{20–25} Prompted by these recent reports, we here present our investigations of incorporation of UAAs into the class I lanthipeptide nisin and the class II lanthipeptide lactacin 481. Our methods are complementary to previous attempts and illustrate approaches to ensure both incorporation of the UAAs and full post-translational modification.

RESULTS AND DISCUSSION

Lactacin 481 was first isolated in the early 1990s from *Lactococcus lactis* subsp. *lactis* CNRZ 481 and exhibits inhibitory activity against a range of indicator strains.²⁶ It is the prototypical member of a large group of natural variants with similar ring topology that includes nukacin ISK-1 and members of the salivaricin family.²⁷ These compounds exhibit diverse antimicrobial potency, but they all contain the mercacidin-like lipid II binding motif within their A-ring (Figure 2).^{10,28–30} During the biosynthesis of lactacin 481, the lanthipeptide synthetase LctM performs both dehydrations and cyclizations on its precursor peptide LctA (Figure 2).³¹ The enzyme first phosphorylates the Ser/Thr targeted for dehydration and then eliminates the phosphate to produce

Received: December 2, 2017

Accepted: February 13, 2018

Published: February 13, 2018




Figure 1. Biosynthesis of the class I lantibiotic nisin A and the post-translational modifications commonly associated with this class of antimicrobial peptides.²

the dehydro amino acids.³² A separate active site catalyzes the addition of Cys residues to the dehydro amino acids.^{33,34} In a previous study, we showed that substituting aromatic residues in the C-ring with UAAs using substrates containing core peptides prepared by solid-phase peptide synthesis (SPPS) could improve the bioactivity of lacticin 481.³⁵ These findings were a good starting point for biological incorporation of UAAs at those positions. In this study, we aimed to investigate the factors required for successful use of stop codon suppression technology for incorporation of UAAs into lantibiotics.

In a recent report, we showed the genetic incorporation of hydroxy-amino acids into lantibiotics using the pyrrolysine tRNA synthetase and its cognate tRNA.²² Using that platform, we herein demonstrate the production of several analogs of lacticin 481 and compare their bioactivities with the parent compound. Pyrrolysine tRNA synthetase (PylRS) and its mutants are robust and versatile enzymes that have been




Figure 2. Biosynthesis of the class II lantibiotic lacticin 481.²

employed to charge pyl-tRNA with several lysine and phenylalanine derivatives.³⁶ We chose the N346A/C348A mutant of the *Methanosarcina mazei* PylRS and its cognate pyl-tRNA to incorporate *o*-Br-Phe, *o*-NO₂-Phe, *m*-Br-Phe, and *m*-CF₃-Phe at three positions (Trp19, Phe21, and Phe23) of lacticin 481.^{37–39} pRSFDuet plasmids were prepared encoding N-terminally His-tagged LctA mutants containing the amber stop codon at each of these positions (W19/F21/F23), LctM, and pyltRNA. These plasmids were used together with a previously reported pEVOL plasmid carrying orthogonal translation machinery.³⁹ Since the mutant PylRS has low selectivity with respect to Phe and its derivatives, and therefore results in background incorporation of Phe in the growing peptide chain, we carried out the coexpressions in synthetic media⁴⁰ lacking Phe. Additionally, to improve the solubility of these analogs, Asn15 in lacticin 481 was mutated to Arg.³⁵ Coexpression of His-tagged-LctA/N15R/TAG mutants, LctM, PylRS, and pyltRNA was carried out in *E. coli* BL21(DE3) in synthetic media supplemented with the desired nonproteinogenic amino acid. After immobilized metal affinity chromatography (IMAC) purification of the peptide, analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) showed the formation of full-length LctA with four dehydrations and containing the UAA.

The incorporation was complete and well-tolerated at all positions for all four Phe derivatives tested (for a representative example, see Figure 3, all other examples are shown in Figures S1–S11). Thus, the lacticin 481 production system in *E. coli* was not affected by the expression of the additional machinery required for UAA incorporation nor by the need to grow in synthetic media. The yields of the peptides were in the range of 0.5–0.8 mg/L without optimization, which is about a 10-fold decrease compared to previous production in *E. coli* without UAA incorporation (5 mg/L).⁴¹ Hence, although the suppression appears highly efficient in Figure 3 and Figures




Figure 3. MALDI-TOF mass spectrum of fully modified LctA-N15R/Trp19 m -CF₃Phe produced by LctM in *E. coli* BL21(DE3). The dashed line shows the position of the expected peptide if stop codon suppression did not occur.

S1–S11, we cannot rule out that the truncated peptide resulting from incomplete stop codon suppression may be degraded in *E. coli*.

Since the first residue of the core peptide is Lys, digestion with endoprotease LysN yielded the lactacin 481 analogs, which were tested for bioactivity against *L. lactis* HP. All mutants were active, with five of the mutants slightly more active than lactacin 481: Trp19 o -ClPhe, Trp19 m -BrPhe, Trp19 o -NO₂Phe, Phe21 o -NO₂Phe, and Phe23 o -ClPhe (Figure 4), similar to previous




Figure 4. Agar diffusion assay of wt-lactacin 481 and its mutants against *L. lactis* HP.

observations with aromatic substitutions at these positions prepared with SPPS.³⁰ Minimal inhibitory concentrations determined in liquid media were 195 nM for Trp19 o -NO₂Phe and 390 nM for Trp19 o -ClPhe, Trp19 m -BrPhe, Phe21 o -NO₂Phe, Phe23 o -ClPhe, and wild type (wt) lactacin 481 (Figure S12). The apparent slightly improved activity on solid medium for the latter four analogs in Figure 4 may be due to different diffusion rates in agar or minor differences in potency that are not picked up in serial 2-fold dilution MIC experiments.

Next, we turned to the class I lantibiotic nisin, which is the best-characterized member of the family. It has been employed in the food industry as a food preservative for the past five decades, and significant bacterial resistance has yet to develop.⁴² Nisin is biosynthesized by two proteins, the

dehydratase NisB and cyclase NisC (Figure 1). The mechanism of dehydration by NisB is fundamentally different from that of the class II dehydratases like LctM that use ATP to phosphorylate the Ser/Thr targeted for dehydration. Instead, NisB uses glutamyl-tRNA to glutamylate the Ser/Thr followed by glutamate elimination to introduce the carbon–carbon double bond.^{43,44} Nisin exerts its antimicrobial activity through a highly potent dual mode of action. The A and B rings recognize and sequester the pyrophosphate moiety of lipid II,⁴⁵ and the C, D, and E rings insert themselves into the membrane, creating pores.^{46–48} Despite the high antimicrobial potency and nontoxicity to humans, nisin is not employed as a human therapeutic, in part because of its low solubility in water, and degradation at acidic and alkaline pH.^{49–53}

We previously reported the heterologous expression of nisin in *E. coli*, which opened up the possibility to investigate the generation of nisin analogs using amber stop codon suppression. Taking into account the positions that improved the bioactivity of nisin in previous site-directed mutagenesis studies,⁵⁴ as well as the positions at which degradation has been reported,⁵⁰ we chose to place amber stop codons at positions encoding Thr2, Ser5, and Met21.

Since a previously reported nisin mutant (Ile4Val/Ser5Phe/Leu6Gly) is a known inhibitor of *Lactococcus lactis* that overcomes the naturally occurring self-protection mechanism,¹² we used this variant as the background sequence for amber stop codon mutation at Ser5. Plasmids were constructed encoding the His-tagged NisA mutants and NisB (in pRSFDuet), NisC, and pyltRNA (in pCDFDuet) and the pylRS mutant and another copy of pyltRNA (in pEVOL). These plasmids were used for coexpression in *E. coli* BL21(DE3) using synthetic media lacking Phe and supplemented with m -Br-Phe and m -CF₃-Phe. Unfortunately, we observed that the full-length peptide with the unnatural amino acid was only partially dehydrated by NisB and that truncants of the peptide were observed in sizable amounts due to incomplete amber codon suppression. As a control, we also expressed wt NisA under these conditions and observed that it also was incompletely dehydrated by NisB (Figure S13), indicating that the incomplete dehydration is not the result of the UAA substitutions. We investigated whether the level of NisB expression was insufficient and switched the media to LB, which previously led to full dehydration,²⁰ but this resulted in substantial decline in stop codon suppression (Figure 5). Thus, unlike the observations for lactacin 481, where the requirements for stop codon suppression did not affect the lantibiotic processing machinery, for nisin the additional burden placed upon the cell requires additional optimization of the post-translational modification process. Similar findings were also recently reported in another study on incorporation of UAAs into nisin.²⁴

To improve the activity of NisB in *E. coli* grown in synthetic media, we expressed multiple copies of NisB (up to three), which afforded a mixture of peptides with improved dehydration (Figure S14), but the issue of incomplete stop codon suppression persisted. While amber stop codons have been widely used for genetic incorporation of UAAs, the method in some cases leads to poor incorporation efficiencies and thus lower yield.^{55–57} This inherent problem is thought to arise in part because of competition between Release Factor 1 (RF1) and the orthogonal tRNA charged with the UAA during peptide synthesis.^{58,59} In prokaryotes, RF1 is responsible for recognizing the amber stop codon UAG and terminating




Figure 5. MALDI-TOF mass spectrum of His₆-NisA-Thr_{2m}-BrPhe coexpressed with NisB and NisC in *E. coli* BL21(DE3) grown in LB.

peptide synthesis.^{58,60} Thus, for an unrestrictive reassignment of the amber codon from a stop signal to an UAA incorporating process, deletion of the *prfA* gene encoding RF1 has been reported by generation of an *E. coli* strain named genomically recoded organism (GRO).⁶¹ In GRO, 321 UAG codons were replaced by synonymous UAA codons, thereby eliminating the basal need for RF1, and the *prfA* gene could be deleted. The GRO provides significant advantages for incorporating UAAs into proteins by amber suppression.⁶² To address the problem of truncation of NisA mutants in our studies, we decided to use an even more evolved GRO developed by Jewett and co-workers.⁶³ This *E. coli* strain (C321.Δ*prfA*-T7RNAPΔ*rne*-Δ*ompT*Δ*lon*) has the T7 polymerase gene inserted and the genes for endonuclease (*rne*) and proteases (*ompT* and *lon*) deleted from the genome. These mutations are used commonly in recombinant protein expression to increase mRNA stability and reduce degradation of heterologous proteins, respectively.^{64–67} Given the cytosolic expression of the lanthipeptides in this work, we suspected that the *rne* and *lon* mutations could provide benefits. Transformation of this strain with the nisin plasmids overcame the problem of NisA truncation. Moreover, we could switch to LB media and observe fully modified full-length nisin analogues as the product for UAA incorporation at positions 2, 5, and 21 (Figures 6 and S15–S17), although the growth rate and cell yields were reduced, presumably because of




Figure 6. MALDI-TOF mass spectrum of NisA-Thr_{2m}-BrPhe modified by NisB and NisC in GRO expressing a single copy of *nisB* grown in LB medium.

the high antibiotic pressure during cell culture (kanamycin, chloramphenicol, and spectinomycin were required to maintain plasmids), the number of proteins being expressed in this GRO, and the lower temperature at which the strain was employed (30 °C). The UAA-containing nisin variants were produced in the range of 0.2–0.5 mg/L prior to leader peptide removal. This corresponds to about a 50–100-fold decrease compared to production of fully modified NisA in *E. coli* without UAA incorporation.²⁰ Because of these low yields, we only tested the Ser^{5m}-BrPhe mutant for bioactivity after trypsin digestion, and it was found to have lower activity than wt nisin (Figure 7).




Figure 7. Agar diffusion assay of wt nisin A (left) and nisin-I4V/Ser^{5m}-BrPhe/L6G (right) against *L. lactis* HP.

Very recently, Schultz and co-workers reported a different strategy to improve the dehydration of nisin mutants containing *para*-substituted-Phe and Lys derivatives.²⁴ In that study, additional copies of *E. coli* tRNA^{Glu}/GluRS were expressed, and *Methanocaldococcus jannaschii* tRNA^{Tyr}/TyrRS or *Methanosarcina barkeri* pyrrolysine tRNA^{Pyl}/PylRS were used for incorporation of the nonproteinogenic amino acid. Our strategy explored a different approach to address the problem of truncation and incomplete dehydration, offering alternative strategies for future studies.

CONCLUSION

In summary, we report two different approaches for the production of lantibiotic variants containing UAAs depending on the demands of the biosynthetic machinery. This study provides a platform for further exploration of bioactivities and stabilities of various lantibiotics including nisin. This work also adds to the growing list of examples of incorporation of UAAs into RiPPs *via* stop codon repression methods.^{20,23,24,68–70}

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acscchembio.7b01024.

Description of all molecular biology procedures, protein purifications, and supporting figures (PDF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: vddonk@illinois.edu.

ORCID

Wenshe R. Liu: 0000-0002-7078-6534

Wilfred A. van der Donk: 0000-0002-5467-7071

Author Contributions

N.K. and W.A.V. designed the study. N.K. performed all experiments. J.G.P., W.R.L., and M.C.J. provided reagents and strains.

Funding

This work was supported by the National Institutes of Health (R37 GM 058822 to W.A.V.), the Human Frontiers Science

Program (Grant RGP0015/2017 to M.C.J.), and the National Science Foundation (MCB-1716766 to M.C.J.). J.G.P. was funded by a National Science Foundation Graduate Research Fellowship. A Bruker UltrafleXtreme MALDI TOF/TOF mass spectrometer was purchased in part with a grant from the National Institutes of Health (S10 RR027109).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors thank M. Gancayco for assistance with initial studies.

REFERENCES

(1) Arnison, P. G., Bibb, M. J., Bierbaum, G., Bowers, A. A., Bugni, T. S., Bulaj, G., Camarero, J. A., Campopiano, D. J., Challis, G. L., Clardy, J., Cotter, P. D., Craik, D. J., Dawson, M., Dittmann, E., Donadio, S., Dorrestein, P. C., Entian, K. D., Fischbach, M. A., Garavelli, J. S., Göransson, U., Gruber, C. W., Haft, D. H., Hemscheidt, T. K., Hertweck, C., Hill, C., Horswill, A. R., Jaspars, M., Kelly, W. L., Klinman, J. P., Kuipers, O. P., Link, A. J., Liu, W., Marahiel, M. A., Mitchell, D. A., Moll, G. N., Moore, B. S., Müller, R., Nair, S. K., Nes, I. F., Norris, G. E., Olivera, B. M., Onaka, H., Patchett, M. L., Piel, J., Reaney, M. J., Rebuffat, S., Ross, R. P., Sahl, H. G., Schmidt, E. W., Selsted, M. E., Severinov, K., Shen, B., Sivonen, K., Smith, L., Stein, T., Süßmuth, R. D., Tagg, J. R., Tang, G. L., Truman, A. W., Vederas, J. C., Walsh, C. T., Walton, J. D., Wenzel, S. C., Willey, J. M., and van der Donk, W. A. (2013) Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. *Nat. Prod. Rep.* 30, 108–160.

(2) Repka, L. M., Chekan, J. R., Nair, S. K., and van der Donk, W. A. (2017) Mechanistic understanding of lanthipeptide biosynthetic enzymes. *Chem. Rev.* 117, 5457–5520.

(3) Velásquez, J. E., and van der Donk, W. A. (2011) Genome mining for ribosomally synthesized natural products. *Curr. Opin. Chem. Biol.* 15, 11–21.

(4) Field, D., Cotter, P. D., Hill, C., and Ross, R. P. (2015) Bioengineering Lantibiotics for Therapeutic Success. *Front. Microbiol.* 6, 1363.

(5) Field, D., Cotter, P. D., Ross, R. P., and Hill, C. (2015) Bioengineering of the model lantibiotic nisin. *Bioengineered* 6, 187–192.

(6) Funk, M. A., and van der Donk, W. A. (2017) Ribosomal natural products, tailored to fit. *Acc. Chem. Res.* 50, 1577–1586.

(7) Dawson, M. J., and Scott, R. W. (2012) New horizons for host defense peptides and lantibiotics. *Curr. Opin. Pharmacol.* 12, 545–550.

(8) Kuipers, O. P., Bierbaum, G., Ottenwälder, B., Dodd, H. M., Horn, N., Metzger, J., Kupke, T., Gnau, V., Bongers, R., van den Bogaard, P., Kusters, H., Rollema, H. S., de Vos, W. M., Siezen, R. J., Jung, G., Götz, F., Sahl, H. G., and Gasson, M. J. (1996) Protein engineering of lantibiotics. *Antonie van Leeuwenhoek* 69, 161–169.

(9) Chen, P., Novak, J., Kirk, M., Barnes, S., Qi, F., and Caulfield, P. W. (1998) Structure-activity study of the lantibiotic mutacin II from *Streptococcus mutans* T8 by a gene replacement strategy. *Appl. Environ. Microbiol.* 64, 2335–2340.

(10) Szekat, C., Jack, R. W., Skutlarek, D., Farber, H., and Bierbaum, G. (2003) Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. *Appl. Environ. Microbiol.* 69, 3777–3783.

(11) Cotter, P. D., Deegan, L. H., Lawton, E. M., Draper, L. A., O'Connor, P. M., Hill, C., and Ross, R. P. (2006) Complete alanine scanning of the two-component lantibiotic lactacin 3147: generating a blueprint for rational drug design. *Mol. Microbiol.* 62, 735–747.

(12) Rink, R., Wierenga, J., Kuipers, A., Kluskens, L. D., Driessen, A. J. M., Kuipers, O. P., and Moll, G. N. (2007) Dissection and modulation of the four distinct activities of nisin by mutagenesis of

rings A and B and by C-terminal truncation. *Appl. Environ. Microbiol.* 73, 5809–5816.

(13) Field, D., Connor, P. M., Cotter, P. D., Hill, C., and Ross, R. P. (2008) The generation of nisin variants with enhanced activity against specific gram-positive pathogens. *Mol. Microbiol.* 69, 218–230.

(14) Islam, M. R., Shioya, K., Nagao, J., Nishie, M., Jikuya, H., Zendo, T., Nakayama, J., and Sonomoto, K. (2009) Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning. *Mol. Microbiol.* 72, 1438–1447.

(15) Cortés, J., Appleyard, A. N., and Dawson, M. J. (2009) Whole-cell generation of lantibiotic variants. *Methods Enzymol.* 458, 559–574.

(16) Ross, A. C., and Vederas, J. C. (2011) Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. *J. Antibiot.* 64, 27–34.

(17) Boakes, S., Ayala, T., Herman, M., Appleyard, A. N., Dawson, M. J., and Cortés, J. (2012) Generation of an actagardine A variant library through saturation mutagenesis. *Appl. Microbiol. Biotechnol.* 95, 1509–1517.

(18) Chen, S., Wilson-Stanford, S., Cromwell, W., Hillman, J. D., Guerrero, A., Allen, C. A., Sorg, J. A., and Smith, L. (2013) Site-directed mutations in the lanthipeptide mutacin 1140. *Appl. Environ. Microbiol.* 79, 4015–4023.

(19) Zhou, L., van Heel, A. J., Montalbán-López, M., and Kuipers, O. P. (2016) Potentiating the activity of nisin against *Escherichia coli*. *Front. Cell Dev. Biol.* 4, 7.

(20) Shi, Y., Yang, X., Garg, N., and van der Donk, W. A. (2011) Production of lantipeptides in *Escherichia coli*. *J. Am. Chem. Soc.* 133, 2338–2341.

(21) Oldach, F., Al Toma, R., Kuthning, A., Caetano, T., Mendo, S., Budisa, N., and Süßmuth, R. D. (2012) Congeneric lantibiotics from ribosomal *in vivo* peptide synthesis with noncanonical amino acids. *Angew. Chem., Int. Ed.* 51, 415–418.

(22) Bindman, N. A., Bobeica, S. C., Liu, W. R., and van der Donk, W. A. (2015) Facile removal of leader peptides from lanthipeptides by incorporation of a hydroxy acid. *J. Am. Chem. Soc.* 137, 6975–6978.

(23) Lopatniuk, M., Myronovskiy, M., and Luzhetskyy, A. (2017) *Streptomyces albus*: A new cell factory for non-canonical amino acids incorporation into ribosomally synthesized natural products. *ACS Chem. Biol.* 12, 2362–2370.

(24) Zambaldo, C., Luo, X., Mehta, A. P., and Schultz, P. G. (2017) Recombinant macrocyclic lanthipeptides incorporating non-canonical amino acids. *J. Am. Chem. Soc.* 139, 11646–11649.

(25) Kuthning, A., Durkin, P., Oehm, S., Hoesl, M. G., Budisa, N., and Süßmuth, R. D. (2016) Towards biocontained cell factories: an evolutionarily adapted *Escherichia coli* strain produces a new-to-nature bioactive lantibiotic containing thienopyrrole-alanine. *Sci. Rep.* 6, 33447.

(26) Piard, J. C., Muriana, P. M., Desmazeaud, M. J., and Klaenhammer, T. R. (1992) Purification and partial characterization of lactacin 481, a lanthionine-containing bacteriocin produced by *Lactococcus lactis* subsp. *lactis* CNRZ 481. *Appl. Environ. Microbiol.* 58, 279–284.

(27) Dufour, A., Hindré, T., Haras, D., and Le Pennec, J. P. (2007) The biology of the lantibiotics of the lactacin 481 subgroup is coming of age. *FEMS Microbiol. Rev.* 31, 134–167.

(28) Brötz, H., Bierbaum, G., Leopold, K., Reynolds, P. E., and Sahl, H. G. (1998) The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. *Antimicrob. Agents Chemother.* 42, 154–160.

(29) Islam, M. R., Nishie, M., Nagao, J., Zendo, T., Keller, S., Nakayama, J., Kohda, D., Sahl, H. G., and Sonomoto, K. (2012) Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) lantibiotic. *J. Am. Chem. Soc.* 134, 3687–3690.

(30) Knerr, P. J., Oman, T. J., Garcia de Gonzalo, C. V., Lupoli, T. J., Walker, S., and van der Donk, W. A. (2012) Non-proteinogenic amino acids in lactacin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation. *ACS Chem. Biol.* 7, 1791–1795.

- (31) Xie, L., Miller, L. M., Chatterjee, C., Averin, O., Kelleher, N. L., and van der Donk, W. A. (2004) Lactacin 481: in vitro reconstitution of lantibiotic synthetase activity. *Science* 303, 679–681.
- (32) Chatterjee, C., Miller, L. M., Leung, Y. L., Xie, L., Yi, M., Kelleher, N. L., and van der Donk, W. A. (2005) Lactacin 481 synthetase phosphorylates its substrate during lantibiotic production. *J. Am. Chem. Soc.* 127, 15332–15333.
- (33) Dong, S. H., Tang, W., Lukk, T., Yu, Y., Nair, S. K., and van der Donk, W. A. (2015) The enterococcal cytolysin synthetase has an unanticipated lipid kinase fold. *eLife* 4, e07607.
- (34) Paul, M., Patton, G. C., and van der Donk, W. A. (2007) Mutants of the zinc ligands of lactacin 481 synthetase retain dehydration activity but have impaired cyclization activity. *Biochemistry* 46, 6268–6276.
- (35) Levegood, M. R., Knerr, P. J., Oman, T. J., and van der Donk, W. A. (2009) In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids. *J. Am. Chem. Soc.* 131, 12024–12025.
- (36) Wan, W., Tharp, J. M., and Liu, W. R. (2014) Pyrrolysyl-tRNA synthetase: an ordinary enzyme but an outstanding genetic code expansion tool. *Biochim. Biophys. Acta, Proteins Proteomics* 1844, 1059–1070.
- (37) Wang, Y. S., Fang, X., Chen, H. Y., Wu, B., Wang, Z. U., Hilty, C., and Liu, W. R. (2013) Genetic incorporation of twelve meta-substituted phenylalanine derivatives using a single pyrrolysyl-tRNA synthetase mutant. *ACS Chem. Biol.* 8, 405–415.
- (38) Tharp, J. M., Wang, Y. S., Lee, Y. J., Yang, Y., and Liu, W. R. (2014) Genetic incorporation of seven ortho-substituted phenylalanine derivatives. *ACS Chem. Biol.* 9, 884–890.
- (39) Wang, Y. S., Fang, X., Wallace, A. L., Wu, B., and Liu, W. R. (2012) A rationally designed pyrrolysyl-tRNA synthetase mutant with a broad substrate spectrum. *J. Am. Chem. Soc.* 134, 2950–2953.
- (40) Hammill, J. T., Miyake-Stoner, S., Hazen, J. L., Jackson, J. C., and Mehl, R. A. (2007) Preparation of site-specifically labeled fluorinated proteins for ¹⁹F-NMR structural characterization. *Nat. Protoc.* 2, 2601–2607.
- (41) Oman, T. J., Knerr, P. J., Bindman, N. A., Velasquez, J. E., and van der Donk, W. A. (2012) An engineered lantibiotic synthetase that does not require a leader peptide on its substrate. *J. Am. Chem. Soc.* 134, 6952–6955.
- (42) Lubelski, J., Rink, R., Khusainov, R., Moll, G. N., and Kuipers, O. P. (2008) Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. *Cell. Mol. Life Sci.* 65, 455–476.
- (43) Garg, N., Salazar-Ocampo, L. M., and van der Donk, W. A. (2013) In vitro activity of the nisin dehydratase NisB. *Proc. Natl. Acad. Sci. U. S. A.* 110, 7258–7263.
- (44) Ortega, M. A., Hao, Y., Zhang, Q., Walker, M. C., van der Donk, W. A., and Nair, S. K. (2015) Structure and mechanism of the tRNA-dependent lantibiotic dehydratase NisB. *Nature* 517, 509–512.
- (45) Hsu, S. T., Breukink, E., Tischenko, E., Lutters, M. A., De Kruijff, B., Kaptein, R., Bonvin, A. M., and Van Nuland, N. A. (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. *Nat. Struct. Mol. Biol.* 11, 963–967.
- (46) Breukink, E., Wiedemann, I., van Kraaij, C., Kuipers, O. P., Sahl, H. G., and de Kruijff, B. (1999) Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. *Science* 286, 2361–2364.
- (47) Brötz, H., Josten, M., Wiedemann, I., Schneider, U., Götz, F., Bierbaum, G., and Sahl, H.-G. (1998) Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. *Mol. Microbiol.* 30, 317–327.
- (48) Wiedemann, I., Breukink, E., van Kraaij, C., Kuipers, O. P., Bierbaum, G., de Kruijff, B., and Sahl, H. G. (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. *J. Biol. Chem.* 276, 1772–1779.
- (49) van Heel, A. J., Montalbán-López, M., and Kuipers, O. P. (2011) Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans. *Expert Opin. Drug Metab. Toxicol.* 7, 675–680.
- (50) Rollema, H. S., Kuipers, O. P., Both, P., de Vos, W. M., and Siezen, R. J. (1995) Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. *Appl. Environ. Microbiol.* 61, 2873–2878.
- (51) Cruz, L., Garden, R. W., Kaiser, H. J., and Sweedler, J. V. (1996) Studies of the degradation products of nisin, a peptide antibiotic, using capillary electrophoresis with off-line mass spectrometry. *J. Chromatogr. A* 735, 375–385.
- (52) Chan, W. C., Bycroft, B. W., Lian, L. Y., and Roberts, G. C. K. (1989) Isolation and characterization of two degradation products derived from the peptide antibiotic nisin. *FEBS Lett.* 252, 29–36.
- (53) Lian, L. Y., Chan, W. C., Morley, S. D., Roberts, G. C., Bycroft, B. W., and Jackson, D. (1992) Solution structures of nisin A and its two major degradation products determined by n.m.r. *Biochem. J.* 283, 413–420.
- (54) Field, D., Begley, M., O'Connor, P. M., Daly, K. M., Hugenholtz, F., Cotter, P. D., Hill, C., and Ross, R. P. (2012) Bioengineered nisin A derivatives with enhanced activity against both Gram positive and Gram negative pathogens. *PLoS One* 7, e46884.
- (55) Wang, L., and Schultz, P. G. (2005) Expanding the genetic code. *Angew. Chem., Int. Ed.* 44, 34–66.
- (56) Chin, J. W. (2011) Reprogramming the genetic code. *EMBO J.* 30, 2312–2324.
- (57) Wals, K., and Ovaas, H. (2014) Unnatural amino acid incorporation in *E. coli*: current and future applications in the design of therapeutic proteins. *Front. Chem.* 2, 15.
- (58) Korostelev, A., Zhu, J., Asahara, H., and Noller, H. F. (2010) Recognition of the amber UAG stop codon by release factor RF1. *EMBO J.* 29, 2577–2585.
- (59) Heinemann, I. U., Rovner, A. J., Aerni, H. R., Rogulina, S., Cheng, L., Olds, W., Fischer, J. T., Soll, D., Isaacs, F. J., and Rinehart, J. (2012) Enhanced phosphoserine insertion during *Escherichia coli* protein synthesis via partial UAG codon reassignment and release factor 1 deletion. *FEBS Lett.* 586, 3716–3722.
- (60) Johnson, D. B., Xu, J., Shen, Z., Takimoto, J. K., Schultz, M. D., Schmitz, R. J., Xiang, Z., Ecker, J. R., Briggs, S. P., and Wang, L. (2011) RF1 knockout allows ribosomal incorporation of unnatural amino acids at multiple sites. *Nat. Chem. Biol.* 7, 779–786.
- (61) Lajoie, M. J., Rovner, A. J., Goodman, D. B., Aerni, H. R., Haimovich, A. D., Kuznetsov, G., Mercer, J. A., Wang, H. H., Carr, P. A., Mosberg, J. A., Rohland, N., Schultz, P. G., Jacobson, J. M., Rinehart, J., Church, G. M., and Isaacs, F. J. (2013) Genomically recoded organisms expand biological functions. *Science* 342, 357–360.
- (62) Amiram, M., Haimovich, A. D., Fan, C., Wang, Y. S., Aerni, H. R., Ntai, I., Moonan, D. W., Ma, N. J., Rovner, A. J., Hong, S. H., Kelleher, N. L., Goodman, A. L., Jewett, M. C., Söll, D., Rinehart, J., and Isaacs, F. J. (2015) Evolution of translation machinery in recoded bacteria enables multi-site incorporation of nonstandard amino acids. *Nat. Biotechnol.* 33, 1272–1279.
- (63) Perez, J. G., Carlson, E. D., Weisser, O., and Jewett, M. C. Improving genomically recoded *Escherichia coli* for the production of proteins containing non-standard amino acids, manuscript in preparation.
- (64) Makino, T., Skretas, G., and Georgiou, G. (2011) Strain engineering for improved expression of recombinant proteins in bacteria. *Microb. Cell Fact.* 10, 32.
- (65) Baneyx, F. (1999) Recombinant protein expression in *Escherichia coli*. *Curr. Opin. Biotechnol.* 10, 411–421.
- (66) Lopez, P. J., Marchand, I., Joyce, S. A., and Dreyfus, M. (1999) The C-terminal half of RNase E, which organizes the *Escherichia coli* degradosome, participates in mRNA degradation but not rRNA processing in vivo. *Mol. Microbiol.* 33, 188–199.
- (67) Rozkov, A., and Enfors, S. O. (2004) Analysis and control of proteolysis of recombinant proteins in *Escherichia coli*. *Adv. Biochem. Eng./Biotechnol.* 89, 163–195.

(68) Tianero, M. D., Donia, M. S., Young, T. S., Schultz, P. G., and Schmidt, E. W. (2012) Ribosomal route to small-molecule diversity. *J. Am. Chem. Soc.* *134*, 418–425.

(69) Piscotta, F. J., Tharp, J. M., Liu, W. R., and Link, A. J. (2015) Expanding the chemical diversity of lasso peptide MccJ25 with genetically encoded noncanonical amino acids. *Chem. Commun.* *51*, 409–412.

(70) Luo, X., Zambaldo, C., Liu, T., Zhang, Y., Xuan, W., Wang, C., Reed, S. A., Yang, P. Y., Wang, R. E., Javahishvili, T., Schultz, P. G., and Young, T. S. (2016) Recombinant thiopeptides containing noncanonical amino acids. *Proc. Natl. Acad. Sci. U. S. A.* *113*, 3615–3620.